Endocrine Abstracts

Introduction and objectives: Poorly differentiated thyroid carcinoma (PDTC) is a rare but aggressive thyroid tumor. PDTC frequently presents in advanced stages and conventional treatments are usually less effective than in differentiated thyroid carcinoma (DTC). Lenvatinib is a multi-kinase inhibitor approved for the treatment of radioiodine-refractory DTC, with significant improvement in progression free survival. Despite the inclusion of a minority PDTC patients in SELECT tr...

Acromegaly is a rare condition and is frequently associated with infertility. There are very few reported cases of pregnancy in these patients, particularly after surgery and radiosurgery. This is a case of a 29-year-old woman with a 1-year history of nasal obstruction, headache and amenorrhea. She was mother of a 5-year-old child and was trying to get pregnant again, unsuccessfully. Clinical examination revealed coarsening of the facial features, hand and feet enlargement, hy...

Introduction: Graves’ disease (GD) is caused by TSH receptor antibodies (TRAbs) which stimulate thyroid activity. Initial treatment usually relies on antithyroid drugs (ATDs), mainly methimazole, carbimazole or propylthiouracil (PTU). These drugs inhibit the enzyme thyroperoxidase, blocking the synthesis of T3 and T4. Definitive therapeutic options include radioactive iodine and total thyroidectomy which are usually reserved for patients who do not tolerate or respond to ...

Introduction: Pazopanib is a tyrosine kinase inhibitor (TKI) considered to be a first-line treatment in adult patients with metastatic clear cell renal cell carcinoma (ccRCC). Thyroid dysfunction, namely hypothyroidism, is now recognized as being an important but potentially manageable side effect induced by such therapy. With this case we aimed to recall an endocrinological complication that can emerge during treatment with TKIs and highlight the importance of a thorough foll...

Introduction: Paraganglioma (PGL) is a neuroendocrine tumor derived from extra adrenal autonomic paraganglia with a germinal mutation rate of 30%. Metastatic paraganglioma (MPGL) can only be predicted after evidence of secondary lesions and it can occur in up to 50% of cases. Clinical course is remarkably variable, but 5-year overall survival is generally around 50%. Treatment options include surgical resection, chemotherapy, radiotherapy, and 123I-MIBG. Being a neu...

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...